XML 55 R35.htm IDEA: XBRL DOCUMENT v3.22.1
Additions and Returns of Product Rights - Narrative (Details)
 1 Months Ended 3 Months Ended 12 Months Ended
Jan. 03, 2022
USD ($)
Nov. 30, 2018
USD ($)
Nov. 30, 2016
USD ($)
shares
Mar. 31, 2022
USD ($)
Mar. 31, 2021
USD ($)
Dec. 31, 2021
USD ($)
installment
Dec. 31, 2020
USD ($)
installment
Dec. 31, 2019
USD ($)
Jul. 31, 2020
USD ($)
Business Acquisition [Line Items]                  
Payment to acquire business upon closing       $ 13,500,000 $ 0        
Goodwill       1,932,876   $ 882,000      
Financial consideration, payment period               2 years  
Financial consideration, number of installments | installment           4 4    
Financial consideration received in exchange for product license rights, installment payments             $ 3,000,000    
Clinigen                  
Business Acquisition [Line Items]                  
Financial consideration received in exchange for product license rights               $ 5,000,000  
Discontinued operations income           $ 2,000,000      
Kyowa Kirin | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement                  
Business Acquisition [Line Items]                  
Upfront payment $ 13,500,000                
Sales milestone payments, maximum $ 3,500,000                
Sales milestone payments, expected       1,500,000          
Kyowa Kirin | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Maximum                  
Business Acquisition [Line Items]                  
Tiered royalty, percent 10.00%                
Vibativ                  
Business Acquisition [Line Items]                  
Payment to acquire business upon closing   $ 20,000,000              
Other Payments to Acquire Businesses   $ 5,000,000              
Percentage of tiered royalty payments (up to)   20.00%              
Tiered royalty payment, threshold   $ 2,500,000              
Additional liability       6,384,586   6,515,627      
Current portion of the contingent consideration liability       2,300,000          
Noncurrent portion of the contingent consideration liability       4,100,000          
Methotrexate                  
Business Acquisition [Line Items]                  
Payment to acquire business upon closing     $ 100,000            
Additional liability           $ 1,000,000     $ 1,000,000
Liability recorded     $ 900,000            
Vested common stock, value       900,000          
Net intangible assets       2,600,000          
Methotrexate | Restricted Stock                  
Business Acquisition [Line Items]                  
Unvested restricted shares (in shares) | shares     180,000            
Sancuso                  
Business Acquisition [Line Items]                  
Other Payments to Acquire Businesses $ 1,200,000                
Additional liability 3,900,000     3,900,000          
Current portion of the contingent consideration liability       1,300,000          
Noncurrent portion of the contingent consideration liability       $ 2,600,000          
Prepaid expenses 300,000                
Inventory 5,200,000                
Goodwill 1,000,000                
Intangible assets $ 12,100,000